DoW Lung Cancer Translational Research Award
Supports advanced translational lung cancer research that moves promising ideas toward clinical application, including late-stage preclinical/correlative studies or pilot clinical trials, for eligible applicants addressing FY26 LCRP areas of emphasis.
⚑ Must address at least one FY26 LCRP area of emphasis · Supports either advanced/late-stage preclinical or correlative studies, or pilot clinical trials of novel interventions · Eligibility section not provided in notice; no sponsor-specific applicant restriction identified in the text
Unit fits — one characterization, each unit's own rules
| Physical Sciences & Engineering (demo) | 80 strong | technical depth: substantial; funds applied research |
| IPPRA | 58 good | portfolio topic: public_health; social/behavioral work is minor; funds applied research; clinical-trial/biomedical core — IPPRA angle is policy/community (capped) |
| Tom Love Innovation Hub | 30 weak | funds applied research; deep-tech content |
Description
Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Translational Research Award (TRA) supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Research must address at least one of the FY26 LCRP areas of emphasis.
Distinctive Features: This funding mechanism intends to support a broad range of translational studies and allows application submission under: Funding Level 1 – Advanced/late-stage preclinical work or correlative studies; or Funding Level 2 – Pilot clinical trials of novel interventions.
Apply
View on Grants.gov → CONTACT: Danielle Reckley Grantor <help@eBRAP.org>